These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18382853)

  • 1. Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction.
    Wing M
    J Immunotoxicol; 2008 Jan; 5(1):11-5. PubMed ID: 18382853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis.
    Walker MR; Makropoulos DA; Achuthanandam R; Van Arsdell S; Bugelski PJ
    Int Immunopharmacol; 2011 Nov; 11(11):1697-705. PubMed ID: 21689786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
    Suntharalingam G; Perry MR; Ward S; Brett SJ; Castello-Cortes A; Brunner MD; Panoskaltsis N
    N Engl J Med; 2006 Sep; 355(10):1018-28. PubMed ID: 16908486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans.
    Wolf B; Morgan H; Krieg J; Gani Z; Milicov A; Warncke M; Brennan F; Jones S; Sims J; Kiessling A
    Cytokine; 2012 Dec; 60(3):828-37. PubMed ID: 22986013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
    Muller PY; Brennan FR
    Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine-release syndrome: overview and nursing implications.
    Breslin S
    Clin J Oncol Nurs; 2007 Feb; 11(1 Suppl):37-42. PubMed ID: 17471824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro cytokine release assays: reducing the risk of adverse events in man.
    Kirton CM; Gliddon DR; Bannish G; Bembridge GP; Coney LA
    Bioanalysis; 2011 Dec; 3(23):2657-63. PubMed ID: 22136053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.
    Ram R; Bonstein L; Gafter-Gvili A; Ben-Bassat I; Shpilberg O; Raanani P
    Am J Hematol; 2009 Apr; 84(4):247-50. PubMed ID: 19260124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome.
    Walker M; Makropoulos D; Achuthanandam R; Bugelski PJ
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):124-35. PubMed ID: 20047153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug trials. Violent reaction to monoclonal antibody therapy remains a mystery.
    Marshall E
    Science; 2006 Mar; 311(5768):1688-9. PubMed ID: 16556805
    [No Abstract]   [Full Text] [Related]  

  • 11. Newer monoclonal antibodies for hematological malignancies.
    Castillo J; Winer E; Quesenberry P
    Exp Hematol; 2008 Jul; 36(7):755-68. PubMed ID: 18565392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotoxicity profile of natalizumab.
    Wehner NG; Gasper C; Shopp G; Nelson J; Draper K; Parker S; Clarke J
    J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products.
    Int J Toxicol; 2008; 27 Suppl 4():1-82. PubMed ID: 19101832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of biologics, lessons learnt from TGN1412.
    Stebbings R; Poole S; Thorpe R
    Curr Opin Biotechnol; 2009 Dec; 20(6):673-7. PubMed ID: 19892543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody-induced cytokine-release syndrome.
    Bugelski PJ; Achuthanandam R; Capocasale RJ; Treacy G; Bouman-Thio E
    Expert Rev Clin Immunol; 2009 Sep; 5(5):499-521. PubMed ID: 20477639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
    Milani C; Castillo J
    Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular engineering and design of therapeutic antibodies.
    Presta LG
    Curr Opin Immunol; 2008 Aug; 20(4):460-70. PubMed ID: 18656541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
    Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
    J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.